Skip to main content

Table 1 Characteristics of COVID-19 ARDS

From: Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study

  All patients (n = 179) Prophylactic Group (n = 108) Therapeutic Group (n = 71) p
Age—median, IQR 62 [51; 70] 61 [51; 70] 64 [53; 71] 0.56
Male—n (%) 130 (72.6) 83 (76.9) 47 (66.2) 0.12
BMI (kg/m2)—median, IQR 30 [26; 34] 29 [26; 33] 31 [27; 34] 0.25
Medical history—n (%)     
 Malignancies/hemopathies 8 (4.5) 4 (3.7) 4 (5.6) 0.79
 Cardiovascular diseases 76 (42.4) 43 (39.8) 33 (46.5) 0.38
 Thrombo-embolic event 9 (5.0) 7 (6.5) 2 (2.8) 0.46
 Cerebrovascular diseases 7 (3.9) 3 (2.8) 4 (5.6) 0.56
 Immune diseases 2 (1.1) 2 (1.9) 0 (0.0) 0.73
 Diabetes 31 (17.3) 13 (12.0) 18 (25.3) 0.02
 Chronic liver disease 3 (1.7) 2 (1.9) 1 (1.4) 1
 Chronic renal disease 16 (8.9) 5 (4.6) 11 (15.5) 0.02
 Respiratory disease 20 (11.2) 12 (11.1) 8 (11.3) 0.97
Baseline severity scores
 SAPS II—median, IQR 47 [37; 63] 48 [37; 63] 47 [38; 62] 0.72
 SOFA—median, IQR 8 [5; 10] 8 [5; 10] 8 [5; 10] 0.90
Anticoagulation treatment in ICU
 LMWH—n (%) 115 (64.2) 87 (80.6) 28 (39.4) < 0.05
 UFH—n (%) 64 (35.8) 21 (19.4) 43 (60.6) < 0.05
Supportive treatments
 Invasive mechanical ventilation—n (%) 179 (100) 108 (100) 71 (100) 1
 RRT—n (%) 35 (19.6) 16 (14.8) 19 (26.8) 0.05
 ECMO—n (%) 11 (6.2) 5 (4.6) 6 (8.5) 0.47
 ECMO duration (days)—median, IQR 7.0 [6.5; 11.0] 7.0 [7.0; 11.0] 8.0 [6.3; 10.5] 1
Outcome
 ICU length of stay (days)—median, IQR 10 [5; 19] 9 [5; 18] 10 [6; 19] 0.27
 ICU mortality—n (%) 31 (17.3) 20 (18.5) 11 (15.5) 0.67
  1. ARDS acute respiratory distress syndrome, BMI body mass index, ECMO extracorporeal membrane oxygenation, ICU intensive care unit, IQR interquartile range, LMWH low molecular weight heparin, RRT renal replacement therapy, SOFA sequential organ failure assessment, SAPSII simplified acute physiology score II, UFH unfractionated heparin